We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioGenes as New Designated Partner in EU Funded Dementia Project
News

BioGenes as New Designated Partner in EU Funded Dementia Project

BioGenes as New Designated Partner in EU Funded Dementia Project
News

BioGenes as New Designated Partner in EU Funded Dementia Project

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioGenes as New Designated Partner in EU Funded Dementia Project"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioGenes GmbH has been chosen as a new partner of cNEUPRO. cNEUPRO is a EU funded research project to analyze neurodegenerative diseases and discover biomarkers, and so improve early and differential diagnosis of Alzheimer’s dementia. BioGenes will provide laboratory facilities and key personnel to develop specific monoclonal antibodies against novel neurochemical dementia biomarkers in blood and cerebrospinal fluid that have been identified during the project. These monoclonal antibodies may not only be used for diagnostics, but also have potential as therapeutic agents since they may access the CNS space. Reliable differential clinical diagnosis of very early dementia stages is crucial for choosing the most effective therapeutic strategy. Recent research has demonstrated that multiparametric neurochemical dementia diagnostics (NDD) in cerebrospinal fluid does improve early and differential diagnosis of dementias. cNEUPRO will establish European standard operation procedures (SOPs) for NDD and first NDD reference centres in Portugal and Hungary. cNEUPRO unites the forces of nineteen biotech and bioinformatic companies as well as leading clinical and proteomic dementia research centres.
Advertisement